NervGen Pharma Corp. Common stock (NGEN) Stock Score, Valuation & Financial Research

NervGen Pharma Corp. Common stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NGEN

NervGen Pharma Corp. Common stock does not currently have a complete Wall Street Score. The stored market price is USD 1.80. These figures are a research snapshot, not a buy or sell recommendation.

What NervGen Pharma Corp. Common stock does

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

NervGen Pharma Corp. is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of neuroreparative therapeutics, specifically targeting spinal cord injury and other neurotraumatic conditions, funded through equity financing and capital raises.

Products and services

  • The company is developing NVG-291, a first-in-class therapeutic candidate for spinal cord injury, and NVG-300, a next-generation candidate for neurotraumatic and neurologic conditions.

Brands and product families

  • NVG-291 — Lead clinical-stage therapeutic candidate for spinal cord injury. Source
  • NVG-300 — Next-generation therapeutic candidate for neurotraumatic and neurologic conditions. Source

Customer types

Healthcare providers and patients with spinal cord injuries and neurotraumatic conditions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company utilizes third-party service providers for clinical trial management, drug development, and manufacturing services. Specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary neuroreparative therapeutic platform (NVG-291) Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NGEN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.80
Market capitalization:
147.54M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -47.43M
Free cash flow:
USD -13.69M
Cash:
USD 61.03M
Total debt:
USD 5.88K
EPS:
USD -0.60

What stands out

  • Free cash flow is USD -13.69M, negative for the stored period.
  • The balance sheet shows USD 61.03M of cash versus USD 5.88K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 61.03M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NGEN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NGEN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NGEN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NGEN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NGEN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research NGEN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.